Strides Arcolab to remain neutral by proposed withdrawal of DEPB scheme

24 May 2011 Evaluate

Strides Arcolab informed that it will not have any impact on the withdrawal of duty entitlement passbook scheme (DEPB). Presently, there are no DEPB claims being made by the company as the company’s exports are from 100% EOU’s.

Recently, the Government of India has proposed the withdrawal of DEPB scheme due to which the company has been receiving queries from the investor community on the impact, if any, on the company in the event that the DEPB scheme is withdrawn.

Besides, Strides Arcolab has received Supreme Court of Victoria’s approval for the scheme implementation agreement between Ascent Pharmahealth, the company’s subsidiary. The scheme will be effective from May 16, 2011 when it will be lodged with the Australian Securities and Investments Commission.

Strides Arcolab is a global pharmaceuticals company headquartered in Bangalore, India that develops and manufactures wide range of IP-led niche pharmaceutical products with an emphasis on sterlite injectables.

Strides Pharma Scien Share Price

913.55 11.20 (1.24%)
01-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1720.40
Dr. Reddys Lab 1253.60
Cipla 1500.10
Zydus Lifesciences 914.50
Lupin 2103.30
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×